The promise of DNA vaccines is as compelling today as it was more than a decade ago. Ease of manufacture, stability at ambient temperatures without the need for a cold chain and its ability to mimic natural infections and elicit appropriate immune responses makes this vaccine platform extremely attractive. Although, human clinical trials of DNA vaccines have yielded less than optimal results, the approval and licensing of a few veterinary vaccines is testimony to the proof-of-concept and the hope that licensed DNA vaccines for human use may not be too far away. Delivery and targeting of immunologically relevant cells appears to be the major hurdle in maximizing the immunogenicity of DNA vaccines. Several different approaches that are currently pursued in achieving this objective are discussed.

中文翻译：

---

DNA 疫苗递送和改进的免疫原性。

今天，DNA 疫苗的前景与十多年前一样令人信服。易于制造、无需冷链即可在环境温度下保持稳定性以及其模拟自然感染和引发适当免疫反应的能力使得该疫苗平台极具吸引力。尽管 DNA 疫苗的人体临床试验产生的结果并不理想，但一些兽用疫苗的批准和许可证明了概念验证，并希望获得许可的用于人类使用的 DNA 疫苗可能不会太远。免疫相关细胞的递送和靶向似乎是最大限度地提高 DNA 疫苗免疫原性的主要障碍。讨论了目前为实现这一目标而采用的几种不同方法。